Accelerate drug development
Peptide-based conjugates are fast to develop because they are modular, making them easy to put together, break apart, and scramble.
What if antibody precision is not enough?
Lytica is a Cambridge-based biotech company developing novel peptide conjugates for next-generation ADCs.
The secret to unlocking more effective ADCs is in the payload
Traditional antibody-drug conjugates combine two technologies into one: targeted antibodies and cytotoxic payloads.
At Lytica, we’re challenging that definition by building unique conjugates that imbue antibodies with new therapeutic properties.
Modular Platform
Our stapled peptide platform enables rapid exploration of ADC combinations
Increase ADC technology compatibility
The modularity of peptides and the stabilizing properties of peptide stapling makes Lytica’s payloads highly compatible with existing antibody and linker technologies.
Unlock previously undruggable targets
Our conjugates allow us to drug new targets, opening up a new landscape of potential target combinations.
